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Background: The efficacy of antimetabolic therapy of malignant neoplasms could not be explained solely by the direct mechanisms 
of action of such energy metabolism inhibitors as sodium dichloroacetate (DCA) and metformin (MTF). The indirect effects of DCA 
and MTF on the organs and tissues, which could play significant role in the antitumor activity of these agents, have not been tho­
roughly explored. Aim: To investigate the effect of MTF, DCA and their combination on the survival of rats with C6 glioma and major 
haematological and biochemical blood parameters. Materials and Methods: DCA and MTF were administered orally to inbred female 
rats for 11 days starting from the second day after tumor cell transplantation at a total dose of 1.1 and 2.6 g/kg, respectively. When 
combined treatment was used, MTF was administered 3 hours after the administration of DCA. The content of lactate and pyruvate 
in blood plasma was determined on the ChemWell® 2910 (Combi) automatic analyzer. Blood parameters were determined using the 
Particle Counter PCE­210 automatic hematology analyzer. Results: The administration of DCA did not significantly affect the life span 
of rats with C6 glioma. Duration of life of rats, which were administered with MTF only, was significantly higher (by 19.1%, p < 0.01). 
Combined administration of DCA + MTF prolonged life span of animals with glioma by 50% (p < 0.001). The positive result of antitumor 
activity of MTF alone and in combination with DCA correlated with a decrease in the mean platelet volume/platelet count (MPV/PLT) 
ratio by 75.0% (p < 0.05) compared with tumor control. In addition, the expressed antitumor effect of combination therapy with DCA 
and MTF was associated with a decrease (p < 0.05) in glucose and lactate levels in blood plasma of rats with C6 glioma by 10% and 
41.4%, respectively, compared to tumor control. Analysis of blood parameters showed that the growth of C6 glioma was accompanied 
by the development of leukopenia, anemia and thrombocytopenia. The introduction of DCA caused the correction of manifestations 
of anemia and leukopenia, but did not affect the level of platelets in the blood of animals with glioma. MTF alone and in combination 
with DCA positively influenced the number of white blood cells and caused complete thrombocytopenia correction, increasing platelet 
count by more than 200% (p < 0.001). Conclusion: The ability of MTF either used alone or in combination with DCA to influence the 
development of C6 glioma which is manifested in an increase in the lifespan of rats has been revealed. The most pronounced antitumor 
effect was recorded against the background of the combined use of these agents, which may be due to their ability to lower the levels 
of lactate and glucose in the blood of tumor­bearing rats. It is proved that MTF both in monotherapy and in combination with DCA 
provides correction of anemia and thrombocytopenia, which arise at the background of glioma C6 growth.
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In the last decade significant progress has �een 
achieved in understanding the mechanisms of repro­
gramming the energy meta�olism of malignant cells� 
and as a result� the efforts of many researchers are 
now aimed at developing a new direction of antitumor 
therapy — antimeta�olic therapy. Therefore� due to high 
antitumor activity� such inhi�itors of energy meta�olism 
as sodium dichloroacetate �DCA� and metformin �MTF� 
have �een widely studied �y oncologists. Both agents 
have long �een used extensively in clinical practice for 
the treatment of pathologies not related to cancer. For 
example� the safety and efficacy of DCA has �een pro­
ven in the case of the correction of lactic acidosis� where 
DCA therapy effectively reduces the level of lactate 
in the �lood �y stimulating the pyruvate oxidation [�]. 
MTF is a hypoglycemic drug that is used as the first line 
of therapy for hyperglycemia and insulin resistance for 
more than �� years. Recent studies have shown that 
the a�ility of MTF to lower �lood glucose levels is due 
to numerous mechanisms� including the activation 
of �'­AMP­activated protein kinase� reduction of cyclic 
AMP production� inhi�ition of �st complex of the elec­
tron transport chain of mitochondria� and others [�].
The features of the energy meta�olism of malignant 
cells associated with the intensification of glycolysis 
and the decrease in ATP production due to mitochon­
drial oxidation have attracted attention of scientists 
to the possi�ilities of using DCA and MTF in oncology 
as potentially simple and effective pharmacological 
agents for treatment of glycolytic malignant tumors. 
Numerous studies of these agents have shown their 
a�ility to exhi�it antitumor properties in many experi­
mental tumor and cell models [3�9]. However� high 
meta�olic plasticity of malignant cells caused sig­
nificant fluctuations in the effectiveness of antitumor 
action of these drugs administered in a monotherapy 
regimen. The most effective approach was the com­
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�ined use of several inhi�itors acting on different 
chains of energy meta�olism [�����].
It should �e noted that the analysis of the results 
of experimental studies suggests that the antitumor 
efficacy of DCA and MTF in in vivo experiments is sig­
nificantly higher than their cytotoxic/cytostatic effects 
on malignant cells in vitro. This is due to the fact that the 
reprogramming of the energy meta�olism of malignant 
cells significantly depends on their microenvironment� 
which is characterized �y a meta�olic deficiency of the 
main energy su�strates due to inadequate vasculariza­
tion of malignant tumors [�3]. The presence or a�sence 
of humoral factors and nutrient su�strates in tumor cells 
microenvironment may also affect the response of these 
cells to DCA­ and MTF­induced reprogramming of en­
ergy meta�olism. Moreover� DCA and MTF may cause 
a decrease in the level of such circulating su�strates 
important for tumor cell survival as glucose and lactate� 
not due to direct action on tumor cells� �ut indirectly 
through the influence on normal organs and systems 
of the �ody. Unfortunately� the study of the influence 
of these agents on the hematological parameters 
of animals with tumors and the possi�le relation with 
their antitumor activity were practically not carried out. 
That is why the aim of this work was to study the effect 
of MTF� DCA and their com�ination on the survival of rats 
with C6 glioma and �asic animal �lood parameters.
MATERIALS AND METHODS
The studies were carried out on in�red female rats 
�.��3 months old weighing ���­�3� g from the vivarium 
of the R.E. Kavetsky Institute of Experimental Pathology� 
Oncology and Radio�iology �IEPOR� of the National 
Academy of �ciences of Ukraine �NA�U�� Kyiv� Ukraine. 
The research on animals was carried out in accordance 
with the provisions of the General Ethical Principles 
of Animal Experiments adopted �y the First Congress 
on Bioethics �Kyiv� ����� and international requirements 
in accordance with the European Convention for the 
Protection of Verte�rate Animals Used for Experimental 
and Other Purposes ��tras�ourg� �9�6�.
As an experimental tumor model� glioma C6 cell line 
was used� which was o�tained from the National Bank 
of Cell Lines and Tumor �trains of IEPOR NA�U. C6 glio ma 
cells were cultured in vitro in DMEM with ��% fetal calf se­
rum ��igma� U�A�� � mM L­glutamine and �� mg/ml gen­
tamicin at 37 °С in humidified atmosphere with �% СО�.
Transfusion of glioma C6 cells was carried out 
under general anesthesia �y intracere�ral inoculation 
of 0.6 • 106 cells in �.�� ml of physiological saline in the 
left parietal zone.
After transplantation� the rats were randomized 
�y weight and distri�uted into � groups: rats� which 
were administered only DCA in a total dose of �.� g/kg 
�n = ���; rats� which were administered with MTF only 
in a total dose of �.6 g/kg �n = ���; rats administered with 
�oth MTF and DCA �n = �3�; rats� which were adminis­
tered with water only �control� n = ���. As intact controls� 
healthy animals were used� the age� gender and weight 
of which fully corresponded to the experimental rats 
at the start of the research. In com�ination therapy� 
the aqueous solution of MTF was administered 3 h af­
ter administration of DCA in the total doses of �.6 and 
�.� g/kg� respectively. The doses of all pharmacologic 
agents studied corresponded to the range of therapeu­
tic doses for rats and were lower than the maximum 
tolerated dose [��].
The agents were dissolved in water and adminis­
tered orally via pro�e n a volume of � ml/animal� once 
daily� starting from the second day after inoculation 
of tumor cells. In total �� administratons were made.
In order to assess the antitumor effect of the agents 
under study with respect to the C6 glioma� the aver­
age life span of animals in each experimental group 
was assessed.
Research of the main �lood indices of rats with 
C6 glioma after treatment with DCA� MTF and their com­
�ination was carried out at the �3th day after inoculation 
of tumor cells. To determine the content of lactate and 
glucose� peripheral �lood was collected in heparin­
ized tu�es� followed �y centrifugation at 3��� rpm� 
and stored at ��� °C until further investigation on a full 
automatic ChemWell® �9�� �Com�i� analyzer. Determi­
nation of hemoglo�in �Hg�� concentration� hematocrit 
�HCT� values� erythrocyte� leukocytes� and platelets 
�PLT� counts� and the calculation of erythrocytic and 
PLT indices in the whole �lood of rats collected in EDTA 
tu�es� was performed using an automatic hematology 
analyzer Particle Counter PCE­���.
�tatistical analysis of the data was performed using 
descriptive methods� correlation analysis� nonlinear re­
gression analysis� �tudents t­criterion� Mann — Whitney 
U­criterion using Microsoft Excel� �tatistic and Micro­
cal Origin software. The data are presented as M ± m� 
where M is the mean value� m is the standard deviation.
RESULTS AND DISCUSSION
The results of the study showed that� after inocu­
lation of glioma C6 cells in� a �rain tumor developed 
in ���% of rats� which �in the a�sence of therapy� 
caused the death of all animals on average in ���
�6 days. Analysis of �lood parameters showed that 
growth of C6 glioma was accompanied �y the deve­
lopment of leukopenia� anemia and throm�ocytopenia� 
whose manifestations can affect the life expectancy 
of rats. Thus� on the �3th day after transplantation 
of tumor cells in the �lood of rats� there was registered 
more than twofold �p < �.��� reduction of the total 
leukocytes �white �lood cells — WBC� counts and� 
respectively� counts of lymphocytes �LY�� monocytes 
�MO� and granulocytes �GR� compared to the corre­
sponding indices in intact animals �Ta�le ��.
Table 1. Leukogram of the rats with glioma C6 after therapy with MTF, 
DCA and their combination
Blood indices Intact rats Tumor control
Тype of therapy
DCA MTF DCA+MTF
WBC (• 103/µl) 10.6 ± 1.2 4.8 ± 1.3# 7.7 ± 3.0 9.3 ± 0.3* 6.7 ± 1.2#
LY (• 103/µl) 7.4 ± 0.7 3.4 ± 1.1# 5.5 ± 2.1 6.2 ± 0.2* 4.5 ± 1.0#
MO (• 103/µl) 1.3 ± 0.1 0.5 ± 0.1# 0.9 ± 0.4 1.2 ± 0.1* 0.8 ± 0.1#
GR (• 103/µl) 1.9 ± 0.4 0.9 ± 0.2# 1.6 ± 0.6 2.0 ± 0.1* 1.4 ± 0.3
Note: *p < 0.05 as compared to tumor control; #p < 0.05 as compared to in-
tact control.
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The development of anemia in rats with C6 glioma 
was confirmed �y a significant �p < �.��� decrease in the 
num�er of red �lood cells �RBC� �y ��.�%� Hg� levels 
�y 9�6% and HCT �y ��6% compared with those for 
healthy animals. At the same time� the type of anemia 
had the character of macrocytic� since mean cell volume 
�MCV�� an index of an average volume of erythrocytes� 
was significantly higher in the �lood of tumor­�earing 
rats than in intact controls ��y 7.�%� p < �����.
However� this did not affect the RBC indices associ­
ated with MCV� i.e. mean cell hemoglo�in �MCH; the 
Hg� content per erythrocyte� and mean corpuscular 
hemoglo�in concentration �MCHC; the Hg� content 
per volume unit of one erythrocyte�� since they were 
within the normal range �Ta�le ��.
In addition to the registered leukopenia and ane­
mia� the growth of C6 glioma was characterized �y the 
development of severe throm�ocytopenia� as shown 
�y a significant decrease �p < �.��� in the counts of PLT 
�y 6��7% and plateletcrit �PCT� �y ����% �Ta�le �� 
as a result of excessive destruction of these cells [��]. 
Moreover� there is a highly heterogeneous PLT popula­
tion in the �lood of rats with a tumor� indicated �y a sig­
nificant increase in their mean volume �MPV� �y �7��% 
�p < �.��� and an increase in the distri�ution width 
�PDW�. This phenomenon occurs in the case of intense 
production of young PLT and their release in the �lood 
from the �one marrow� which actively compensates 
their destruction [�6].
Influence of MTF, DCA and their combination 
on survival of rats with C6 glioma and blood indi-
ces of animals. It was found that due to the ��­day­
long therapy with DCA� MTF and their com�ination� the 
positive antitumor effect on C6 glioma was recorded 
in the groups of rats receiving MTF alone or a com­
�ination of MTF and DCA. While DCA therapy did not 
affect the life span of rats with C6 glioma� the intro­
duction of MTF statistically significantly lengthened 
the life span of rats with tumors �y �9.�% �p < �.���� 
and the com�ined administration of the agents gave 
a significant antigliomic effect and prolongation of life 
of the animals �y ��% �p < �.����. It should �e noted 
that the high effectiveness of antitumor com�ined 
therapy with these agents was most likely due to syn­
ergistic effects of MTF and DCA on the development 
of C6 glioma �Fig. ��.
In the a�sence of antitumor activity of DCA against 
C6 glioma� the administration of this agent caused 
a positive effect on some indices of �oth red and white 
cell lineages of peripheral �lood in rats.
Analysis of hemogram data after DCA therapy 
indicated that this agent has the a�ility to correct the 
manifestations of anemia in rats with C6 glioma. That 
is� the levels of RBC� Hg� and HCT in the �lood of the 
experimental group of animals were within the normal 
limits �Ta�le ��� which indicated the normal functional 
a�ility of erythrocytes to carry oxygen. A low� how­
ever� significant �p < �.��� increase in the MCV index 
�y �.7% in the �lood of tumor­�earing animals after 
treatment with DCA may �e due not only to the glioma 
development �ut also to the direct effect of DCA� since 
intake of this agent may �e accompanied �y the defi­
ciency of vitamins of group B in the �ody� which mani­
fests itself in reducing the proportion of RBC against 
the �ackground of their increased volume.
There was also recorded a marked tendency 
to increase of the total level of leukocytes in rats after 
administration of DCA practically to the level of this 
in intact animals �Ta�le ��. The a�sence of statistically 
significant results is due to the large range of deviations 
characteristic of the studied parameters in the group 
of animals administered with DCA.
The study of PLT counts and PLT indices showed 
that DCA did not affect the development of throm�o­
cytopenia in rats with transplanted tumors. Despite the 
lack of significant changes in HCT� the level of PLT in the 
Table 2. Hemogram of the rats with glioma C6 after therapy with MTF, DCA and their combination
Blood indices Intact rats Tumor control Тype of therapyDCA MTF DCA + MTF
RBC, • 106/µl 7.1 ± 0.1 6.0 ± 0.1# 6.8 ± 0.3* 6.6 ± 0.4 7.1 ± 0.6*
Hgb, g/dl 12.5 ± 0.2 11.3 ± 0.4# 11.9 ± 0.8 12.0 ± 0.3 12.1 ± 0.8
HCT, % 45.4 ± 0.9 41.5 ± 1.4# 45.3 ± 2.4 46.4 ± 1.4 47.2 ± 2.8*
MCV, fl 63.9 ± 0.7 68.9 ± 1.2 66.9 ± 0.8 70.2 ± 2.1 67.9 ± 1.0
MCH, pg 17.6 ± 0.3 18.8 ± 0.3 17.6 ± 0.5 18.1 ± 0.9 17.1 ± 0.3*
MCHC, g/dl 27.5 ± 0.2 27.2 ± 0.3 26.2 ± 0.5* 25.8 ± 0.4#,* 25.6 ± 0.3*
RDW, % 17.9 ± 0.3 18.2 ± 0.5 18.3 ± 0.7 18.2 ± 0.3 20.5 ± 1.6
PLT, • 103/µl 311.0 ± 41.0 116.0 ± 54.4# 182.3 ± 49.7# 381.7 ± 12.6** 357.3 ± 57.5*
PCT, % 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.3 ± 0.0* 0.3 ± 0.0*
MPV, fl 7.4 ± 0.3 9.4 ± 0.9 9.2 ± 0.4# 7.8 ± 0.2 7.8 ± 0.4
PDW, fl 27.1 ± 2.3 27.7 ± 1.4 29.5 ± 0.2 29.1 ± 0.1 28.5 ± 0.9
Note: *p < 0.05 as compared to tumor control; **p < 0.001 as compared to tumor control; #p < 0.05 as compared to intact control.
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Fig. 1. The average life expectancy of the glioma C6 �earing 
rats in the groups treated with DCA� MTF or their com�ination.
*p < �.�� as compared to control; **p < �.��� as compared 
to control
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�lood of rats with C6 glioma after action of DCA was 
almost at the level of tumor control and was lower than 
that in intact controls �y ��.�% �p < �.���. As can �e seen 
from Ta�le �� the MPV level in the studied animals groups 
was higher than in intact control �y ��.3% �p < �.���� 
and PDW tended to increase� indicating a predominance 
of young PLT in the �lood of this group of rats at the 
�ackground of destruction of mature ones.
In contrast to DCA� the introduction of MTF caused 
a complete normalization of �lood leucogram in the 
animals. As a result of �� day­long treatment with MTF� 
the level of WBC and� respectively� LY� MO and GR did 
not differ from those in intact animals and significantly 
�p < �.��� exceeded the corresponding tumor control 
parameters �y 93.�; ��.�; ���.� and ���.�% �Ta�le ��. 
The o�tained data confirm the a�ility of MTF to normal­
ize the immune system� as previously demonstrated 
in the study on the role of the immune system in the 
mechanisms of the therapeutic effect of MTF in pa­
tients with type II dia�etes mellitus [�7].
The most significant positive changes after MTF 
therapy were recorded in the indicators of the PLT 
�ranch of hematopoiesis. As can �e seen from Ta�le �� 
PLT count significantly increased �y �3�% �p < �.���� 
compared with tumor control� reaching the level of this 
index in the �lood of intact rats. At the same time� the 
MTF had a weak �ut positive effect on the erythrocytic 
�ranch of hematopoiesis: levels of RBC� Hg�� HCT� 
RDW and MCH did not differ from the corresponding 
indices of intact rats. An insignificant increase in the 
volume of erythrocytes in the �lood of investigated 
animals may �e due to the fact that MTF has the a�ility 
to accumulate in RBC� there�y playing the role of depot 
of MTF in the �ody [�����].
It was shown that due to the com�ined therapy with 
inhi�itors of energy meta�olism� MTF and DCA� the 
level of WBC in the �lood of rats with glioma somewhat 
increased ��y 36.�%� p < �.��� in comparison with the 
control group �ut still was significantly lower than the 
corresponding index in healthy animals� mainly due 
to the significant �p < �.��� decrease of the LY level 
�y 39.�% �Ta�le ��.
The analysis of the hemogram �Ta�le �� showed 
that the com�ined therapy with MTF and DCA pro­
vided the correction of anemia and throm�ocytopenia 
more likely due to the direct effect of MTF on these 
�lood indices. The latter is evidenced �y the a�sence 
of significant differences �etween hemograms of rats 
treated with MTF or com�ined therapy.
As it is known� under physiological conditions� 
the PLT count in the �lood is in equili�rium� which 
is supported �y a constant ratio of regeneration and 
elimination. At the same time� the throm�ocrit value� 
reflecting the percentage of PLT volume in the total 
volume of �lood� is directly related to the num�er 
of PLT� whereas the MPV index is inversely proportional 
to these values [����3]. MPV is considered a good 
marker for differential diagnosis of throm�ocytopenia. 
An increase in this index is o�served in a hyperdestruc­
tive form [����6] and in the case of tumor disease 
it is supposed to �e associated with a negative prog­
nosis. It is worth noting that today the MPV/PLT ratio 
is considered as one of the markers of the effective­
ness of antitumor therapy [�7� ��]. At the same time� 
the decrease of this index to the level typical of healthy 
animals indicated the effectiveness of therapy. The 
analysis of the o�tained results allowed to calculate the 
average value and find the range of values of the MPV/
PLT ratio for healthy animals� animals with C6 glioma 
and tumor­�earing rats treated with MTF� DCA and 
their com�ination.
It was shown� that the growth of C6 glioma is charac­
terized �y the statistically signfcant increase of MPV/
PLTs ratio �y 3��% compared with the corresponding 
indices of intact control �Ta�le 3�. The use of MTF and 
MTF in com�ination with DCA significantly reduced 
this index �y 7�.�% �p < �.��� compared with tumor 
control� which correlated with the positive result 
of antitumor therapy. Despite the tendency to decrease 
of the MPV/PLT ratio in the animal group after DCA 
therapy� no significant changes were recorded for this 
index compared to tumor control� which correlated 
with the a�sence of antitumor efficacy of DCA therapy 
of C6 glioma.
Table 3. Influence of MTF, DCA and their combination on MPV/PLT ratio 
in the blood of glioma C6 bearing rats
Intact  
control
Rats with glioma C6
Control DCA MTF DCA+MTF
MPV/PLT 0.02 0.08# 0.05 0.02* 0.02*
Range of
(MPV/PLT) 0.02–0.029 0.05–0.167 0.037–0.0720.019–0.0270.019–0.021
Note: *p < 0.05 as compared to tumor control; #p < 0.05 as compared to in-
tact rats.
It is known that �rain tumors are characterized 
�y intense glycolysis and are highly dependent on the 
circulating glucose [�9]. Therefore� the influence 
of DCA and MTF com�inaton on the level of lactate and 
glucose may contri�ute to their expressed anti­glioma 
effect. The main antitumor effect of DCA is �elieved 
to �e realized due to its a�ility to activate oxidative 
phosphorylation in tumor cells and depolarize the 
mitochondrial mem�rane� which causes increased 
production of active oxygen species� and� as a con­
sequence� induction of apoptosis [3�]. On the other 
hand� MTF is a hypoglycemic agent widely used in the 
treatment of type II dia�etes mellitus in order to reduce 
�lood glucose levels. In addition� it is an inhi�itor of the 
Ist complex of the electron transport chain of mito­
chondria� and at the initial respiratory stage� it is a�le 
to “shut off” the Kre�s cycle.
As can �e seen from Fig. �� the growth of C6 glioma 
was accompanied �y a statistically significant de­
crease in glucose level in peripheral �lood of animals 
�y ��% �p < �.���� which was most likely due to the 
high need of glycolytic tumor in the level of this energy 
su�strate. Interestingly� after administration of either 
DCA� or MTF� glucose levels in rat �lood increased 
almost to the level of intact animals.
In the case of DCA� this may �e due to the inten­
sification of oxidative phosphorylation and inhi�ition 
of glycolysis in the cells of the �ody �y redirecting py­
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ruvate to the Kre�s cycle. In favor of this evidenced the 
decrease in the level of lactate in the peripheral �lood 
of rats after the introduction of DCA. In the case of MTF� 
an increase in glucose levels in rat �lood can occur 
due to effective anti­glioma activity� and as a conse­
quence of reducing the need of tumor in glucose. The 
most pronounced changes in �oth glucose and lactate 
levels were o�served in rats after com�ined therapy 
with DCA and MTF. Decrease of glucose level �y ��% 
�p < �.��� in comparison with this index of tumor con­
trol can �e directly related to the high antitumor effect 
of com�ined therapy. However� a significant decrease 
in the level of lactate �y ��.�% �p < �.��� indicated the 
a�ility of this com�ination of agents to significantly reduce 
the intensity of glycolysis� a factor that can make a signifi­
cant contri�ution to the antitumor activity of com�ination 
therapy. The question — in which cells �normal or tumor 
ones� DCA and MTF are capa�le to significantly inhi�it 
glycolysis� remains open and requires additional research.
CONCLUSION
Thus� this work demonstrated the a�ility of MTF 
either used alone or in com�ination with DCA to influ­
ence the development of C6 glioma which is mani­
fested in an increase in the lifespan of rats. The most 
pronounced antitumor activity was recorded against 
the �ackground of the com�ined use of these inhi�itors 
of energy meta�olism� which was shown to lengthen 
the life span of rats with C6 glioma �y ��% �p < �.����. 
In this case� the expressed anti­glioma effect of MTF 
in com�ination with DCA may �e related to the a�ility 
of these agents to reduce the levels of lactate and glu­
cose in the �lood of tumor­�earing rats. It is proved that 
MTF� used as monotherapy or in com�ination with DCA� 
provided the correction of anemia and throm�ocytope­
nia developing at the �ackground of C6 glioma growth.
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